Showing 3751-3760 of 5621 results for "".
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023https://modernod.com/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023/2481955/Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference held in San Francisco on Thursday, November 2, 2023. During the conference, Samuel Barone, MD, Nanoscope's chief
- ASCRS Names Abigail Markward New Executive Directorhttps://modernod.com/news/ascrs-names-abigail-markward-new-executive-director/2481952/The American Society of Cataract and Refractive Surgery (ASCRS) has named Abigail Markward as the new Executive Director of the ASCRS Foundation. Ms. Markward has more than two decades of expertise in strategic communications, marketing, publishing, and nonprofit roles. Most recent
- Kiora’s KIO-301 Molecular Photoswitch Evaluated for Retinitis Pigmentosa in ABACUShttps://modernod.com/news/kioras-kio-301-molecular-photoswitch-evaluated-for-retinitis-pigmentosa-in-abacus/2481946/Kiora Pharmaceuticals announced topline results of a phase 1/2 clinical trial demonstrating proof-of-concept that KIO-301, the company’s first-in-class intravitreal (IVT) molecular photoswitch, has the potential to meaningfully improve vision in patients with retinitis pigmentosa (RP)
- Belite Bio’s Tinlarebant Studied to Treat Childhood-onset Stargardt Diseasehttps://modernod.com/news/belite-bios-tinlarebant-studied-to-treat-childhood-onset-stargardt-disease/2481950/Belite Bio presented final data from a 24-month, phase 2 study of Tinlarebant (LBS-008) in adolescent Stargardt disease (STGD1). The study—LBS-008-CT02—enrolled 12 adolescent STGD1 patients, aged 12-18 years, who completed
- Topcon Introduces Tempo Perimeter at AAO 2023https://modernod.com/news/topcon-introduces-tempo-perimeter-at-aao-2023/2481942/Topcon announced that it is launching the Tempo Perimeter at the American Academy of Ophthalmology (AAO) meeting in San Francisco. Tempo is designed to provides fast, accurate, and comfortable visual field testing, according to Topcon. It is 39% faster than Stan
- Ace Vision Group Adds Four Ophthalmologists to Medical Advisory Board; Launches New Corporate and Medical Affairs Websiteshttps://modernod.com/news/ace-vision-group-adds-four-ophthalmologists-to-medical-advisory-board-launches-new-corporate-and-medical-affairs-websites/2481941/Ace Vision Group announced the addition of Cathleen McCabe, MD; James Katz, MD; Ehsan Sadri, MD; and Dagny Zhu, MD, to its medical advisory board. These prominent ophthalmologists will contribute expertise to advance the development and implementation of novel solutions for e
- Ora and BlindCAN Film Festival Unveil 'The Blind Canvas Project' Using AI to Visualize the Human Experience of Blindnesshttps://modernod.com/news/ora-and-blindcan-film-festival-unveil-the-blind-canvas-project-using-ai-to-visualize-the-human-experience-of-blindness/2481937/Ora and BlindCAN Film Festival announced the launch of 'The Blind Canvas Project,' which aims to use storytelling and generative artificial intelligence (AI) to foster a deeper understanding of the lives and experiences of people living with inherited retinal disease, childhood visua
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with